A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.

PubWeight™: 8.60‹?› | Rank: Top 0.1%

🔗 View Article (PMID 7529341)

Published in JAMA on January 25, 1995


P H Gann1, C H Hennekens, M J Stampfer

Author Affiliations

1: Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School.

Associated clinical trials:

Physicians' Health Study | NCT00000500

Articles citing this

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet (2014) 11.01

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ (2013) 3.51

Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ (2009) 3.00

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90

Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ (1995) 2.80

A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 2.39

What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25

Cancer diagnosis in primary care. Br J Gen Pract (2010) 2.24

Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health (2000) 1.99

PSA screening and prostate cancer mortality. CMAJ (2002) 1.98

Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ (1998) 1.77

Adjusting for covariate effects on classification accuracy using the covariate-adjusted receiver operating characteristic curve. Biometrika (2009) 1.70

Risk-based prostate cancer screening. Eur Urol (2011) 1.64

Prostate specific antigen testing among the elderly--when to stop? J Urol (2009) 1.62

Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet (2000) 1.58

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57

Prostate cancers in men with low PSA levels--must we find them? N Engl J Med (2004) 1.52

Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst (2012) 1.50

Calibrating disease progression models using population data: a critical precursor to policy development in cancer control. Biostatistics (2010) 1.42

Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40

Current status of PSA screening. Early detection of prostate cancer. Can Fam Physician (2004) 1.39

Screening without evidence of efficacy. BMJ (2004) 1.39

Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract (2004) 1.34

Prostate cancer: 4. Screening. CMAJ (1998) 1.34

Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol (1997) 1.32

Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28

The development of a web- and a print-based decision aid for prostate cancer screening. BMC Med Inform Decis Mak (2010) 1.21

Prostate cancer: diagnosis and staging. Asian J Androl (2008) 1.21

Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen. World J Urol (1997) 1.20

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev (2010) 1.18

Modeling Disease Progression with Longitudinal Markers. J Am Stat Assoc (2008) 1.13

Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. J Proteome Res (2009) 1.13

Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ (2003) 1.12

Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. Br J Cancer (2006) 1.11

Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res (2008) 1.11

Screening for prostate cancer: an update. Can J Urol (2008) 1.11

Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J Proteomics (2009) 1.03

Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels. J Gen Intern Med (2000) 1.02

Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer (2001) 0.99

Psychological and screening profiles of first-degree relatives of prostate cancer patients. J Behav Med (2001) 0.96

Does PSA screening reduce prostate cancer mortality? CMAJ (2002) 0.95

Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol (2004) 0.95

Predictive Factors for Prostate Cancer in Biopsy of Patients with Prostate-Specific Antigen Levels Equal to or Less Than 4 ng/ml. Korean J Urol (2011) 0.95

Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet (2001) 0.93

Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract (2002) 0.92

Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. Health Serv Res (1999) 0.92

Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer (2007) 0.89

Predicting prostate cancer many years before diagnosis: how and why? World J Urol (2011) 0.89

Prostate-specific antigen screening: pro. Curr Opin Urol (2010) 0.88

Detection of prostate cancer. Recent evidence suggests screening may be justified in high risk younger men. BMJ (1995) 0.86

Does current evidence justify prostate cancer screening in Europe? Nat Clin Pract Oncol (2005) 0.86

The diet as a cause of human prostate cancer. Cancer Treat Res (2014) 0.86

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. Curr Opin Urol (2009) 0.85

Prostate-specific antigen testing of older men. J Natl Cancer Inst (1999) 0.85

Homogeneous prostate cancer mortality in the Nordic countries over four decades. Eur Urol (2010) 0.85

Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer (2008) 0.84

Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate. World J Urol (1997) 0.82

Prostate-specific antigen screening and mortality from prostate cancer. J Gen Intern Med (2008) 0.81

Development of a real-time clinical decision support system upon the Web MVC-based architecture for prostate cancer treatment. BMC Med Inform Decis Mak (2011) 0.80

Commentary: prostate cancer is omnipresent, but should we screen for it? Int J Epidemiol (2007) 0.78

Prostate cancer testing following a negative prostate biopsy: over testing the elderly. J Gen Intern Med (2007) 0.78

Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer. Front Oncol (2016) 0.78

Is prostate biopsy essential to diagnose prostate cancer in the older patient with extremely high prostate-specific antigen? Korean J Urol (2012) 0.78

Kallikreins as biomarkers for prostate cancer. Biomed Res Int (2014) 0.77

Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. Br J Cancer (1996) 0.77

Biopsy follow-up of prostate-specific antigen tests. Am J Prev Med (2012) 0.77

Screening Prostate-specific Antigen Concentration and Prostate Cancer Mortality: The Korean Heart Study. Urology (2015) 0.76

New information about prostate-specific antigen and the paradoxes of prostate cancer. JAMA (1995) 0.75

A Urologist's Personal View of Prostate Cancer. Turk J Urol (2016) 0.75

The utility of prostate-specific antigen for detecting prostate cancer. JAMA (1995) 0.75

Brief report: Free prostate-specific antigen test utilization. Consistency with guidelines. J Gen Intern Med (2005) 0.75

The utility of prostate-specific antigen for detecting prostate cancer. JAMA (1995) 0.75

Expectant management of prostate cancer. Rev Urol (2003) 0.75

Adding free to total prostate-specific antigen levels in trials of prostate cancer screening. Br J Cancer (2000) 0.75

The utility of prostate-specific antigen for detecting prostate cancer. JAMA (1995) 0.75

The utility of prostate-specific antigen for detecting prostate cancer. JAMA (1995) 0.75

Screening for prostate cancer today. West J Med (1995) 0.75

The utility of prostate-specific antigen for detecting prostate cancer. JAMA (1995) 0.75

Should we and can we cure prostate cancer? West J Med (1996) 0.75

Prostate cancer in the West African sub-region, the need to know. J West Afr Coll Surg (2012) 0.75

Prostate-specific antigen reduction after empiric antibiotic treatment does not rule out biopsy in patients with lower urinary tract symptoms: prospective, controlled, single-center study. Prostate Int (2017) 0.75

Articles by these authors

Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol (1985) 26.13

Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04

Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol (1992) 17.17

Total energy intake: implications for epidemiologic analyses. Am J Epidemiol (1986) 16.34

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med (2001) 14.48

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08

Body weight and mortality among women. N Engl J Med (1995) 11.04

Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol (1989) 10.98

Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol (1986) 10.84

Validity of self-reported waist and hip circumferences in men and women. Epidemiology (1990) 10.57

Reproducibility and validity of a self-administered physical activity questionnaire. Int J Epidemiol (1994) 9.90

Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc (1993) 9.90

Aspirin and the risk of colorectal cancer in women. N Engl J Med (1995) 9.59

Dietary fat and coronary heart disease: a comparison of approaches for adjusting for total energy intake and modeling repeated dietary measurements. Am J Epidemiol (1999) 9.34

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28

Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med (1990) 8.98

Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med (1991) 8.66

Prospective study of alcohol consumption and risk of coronary disease in men. Lancet (1991) 8.64

Test of the National Death Index. Am J Epidemiol (1984) 8.46

Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med (1997) 8.43

Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA (1989) 8.36

Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17

Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet (1991) 7.87

Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care (1994) 7.11

Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA (1998) 7.09

Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire. Am J Clin Nutr (1999) 7.02

Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA (1997) 6.92

An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation (1989) 6.87

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50

Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol (1994) 6.47

The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med (2001) 6.37

Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med (1993) 6.37

Physical activity and television watching in relation to risk for type 2 diabetes mellitus in men. Arch Intern Med (2001) 6.23

Abdominal adiposity and coronary heart disease in women. JAMA (1998) 6.21

Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med (1999) 6.17

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med (1991) 6.13

A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med (1990) 6.06

A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med (1993) 5.87

Triggering of sudden death from cardiac causes by vigorous exertion. N Engl J Med (2000) 5.63

The assessment of alcohol consumption by a simple self-administered questionnaire. Am J Epidemiol (1991) 5.60

Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med (1995) 5.42

Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med (1994) 5.42

Vitamin E consumption and the risk of coronary disease in women. N Engl J Med (1993) 5.39

The use of a self-administered questionnaire to assess diet four years in the past. Am J Epidemiol (1988) 5.32

Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA (1993) 5.31

Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999) 5.27

Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med (1993) 5.19

A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med (2000) 5.17

Prospective study of major dietary patterns and risk of coronary heart disease in men. Am J Clin Nutr (2000) 5.17

A prospective cohort study of vasectomy and prostate cancer in US men. JAMA (1993) 5.09

Intake of trans fatty acids and risk of coronary heart disease among women. Lancet (1993) 5.00

Postmenopausal hormone therapy and mortality. N Engl J Med (1997) 4.96

A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med (1995) 4.94

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation (1998) 4.89

Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med (2000) 4.84

Dual effects of weight and weight gain on breast cancer risk. JAMA (1997) 4.81

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation (1998) 4.80

Dietary fat and fiber in relation to risk of breast cancer. An 8-year follow-up. JAMA (1992) 4.80

Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA (1995) 4.78

Menopause and the risk of coronary heart disease in women. N Engl J Med (1987) 4.70

Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst (1996) 4.66

Weight as a risk factor for clinical diabetes in women. Am J Epidemiol (1990) 4.64

A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med (1999) 4.61

A prospective study of passive smoking and coronary heart disease. Circulation (1997) 4.51

A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA (1997) 4.50

Birth weight and risk of cardiovascular disease in a cohort of women followed up since 1976. BMJ (1997) 4.49

Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann Intern Med (1999) 4.49

Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care (1997) 4.46

Cigarette smoking, relative weight, and menopause. Am J Epidemiol (1983) 4.46